Johnson & Johnson Innovation joined in the $60.75 million series A funding round for SonoThera, a biotech genetic therapy company.
SonoThera created an ultrasound-guided, non-viral gene therapy platform designed to provide patients with genetic medicines via sonoporation. The financing will be used to support the continued development of the platform, according to a Dec. 5 SonoThera news release.
The round was led by Arch Venture Partners.